152460-06-5

Basic information

• Product Name: 1,3-Benzenediamine, N-[4-(3-pyridinyl)-2-pyrimidinyl]-
• CAS NO: 152460-06-5
• Molecular Formula: C15H13N5
• Molecular Weight: 263.302
• Mol File: 152460-06-5.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 1,3-Benzenediamine, N-[4-(3-pyridinyl)-2-pyrimidinyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzenediamine, N-[4-(3-pyridinyl)-2-pyrimidinyl]-(152460-06-5)
• EPA Substance Registry System: 1,3-Benzenediamine, N-[4-(3-pyridinyl)-2-pyrimidinyl]-(152460-06-5)

Safety Data

• Hazardous Substances Data: 152460-06-5(Hazardous Substances Data)

Upstream product

• 7440-05-3 palladium 
• 152459-75-1 N-(3-nitrophenyl)-4-(pyridin-3-yl)-2-pyrimidine-amine 
• 55314-16-4 (E)-3-(dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 142992-99-2 N-(3-nitro-phenyl)-guanidine nitrate 

Downstream Products

• 475587-06-5 4-(chloromethyl)-N-(3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide 
• 1399843-24-3 maleopimaric acid N-{3-[4-(pyridin-3-yl)pyrimidin-2-yl-amino]phenyl}amide 
• 1143460-14-3 methyl 4-(3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenylcarbamoyl)benzoate 
• 1143459-94-2 {2-[(1-{4-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-phenyl}-methanoyl)-amino]-phenyl}-carbamic acid tert-butyl ester 
• 1143459-76-0 N₁-methyl-N₃-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine 
• 623901-00-8 4-amino-N-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide 
• 623900-98-1 4-nitro-N-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide 

Relevant articles and documents

Catalytic Activity of Nickel Nanoparticles in the Reaction of Reduction of Nitroarenes

Techniques for the production of nickel and nickel-cobalt nanoparticles and of their composites with polyvinylpyrrolidone were developed. The catalytic activity of the resulting compounds towards reduction of substituted nitroarenes was examined.

Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: A series of Imatinib hybrides as potent Inhibitors of wild-type and mutant BCR-ABL, PDGF-Rβ, and histone deacetylases

Inhibitors of histone deacetylases are a new class of cancer therapeutics with possibly broad applicability. Combinations of HDAC inhibitors with the kinase inhibitor 1 (Imatinib) in recent studies showed additive and synergistic effects. Here we present a new concept by combining inhibition of protein kinases and HDACs, two independent pharmacological activities, in one synthetic small molecule. In general, the HDAC inhibition profile, the potencies, and the probable binding modes to HDAC1 and HDAC6 were similar as for 6 (SAHA). Inhibition of Abl kinase in biochemical assays was maintained for most compounds, but in general the kinase selectivity profile differed from that of 1 with nearly equipotent inhibition of the wildtype and the Imatinib resistant Abl T315I mutant. A potent cellular inhibition of PDGFR and cytotoxicity toward EOL-1 cells, a model for idiopathic hypereosinophilic syndrome (HES), are restored or enhanced for selected analogues (12b, 14b, and 18b). Cytotoxicity was evaluated by using a broad panel of tumor cell lines, with selected analogues displaying mean IC50 values between 3.6 and 7.1 μM.

N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.